Home > Newsletters > FDAnews Drug Daily Bulletin > Impax in ‘Precarious Position’ as Key Products Face Competition: Analyst
FDAnews Drug Daily Bulletin
Nov. 8, 2012 | Vol. 9 No. 220
Impax in ‘Precarious Position’ as Key Products Face Competition: Analyst
Impax Laboratories’ reliance on a few key products — two generics and one brand drug — for the bulk of its revenue is likely to hurt the company in the near future as it loses its near monopoly on the drugs. Compounded with the impact of a warning letter for its Hayward, Calif., manufacturing facility that continues to prevent ANDA and NDA approvals, Impax is in a “precarious position,” Jefferies analyst Corey Davis said Oct. 31. Davis’ comments come after the company’s third-quarter earnings call last week.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.